To what extent does the prostate‐specific antigen nadir predict subsequent treatment failure after transrectal high‐intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?

OBJECTIVE To explore the association between the prostate‐specific antigen (PSA) nadir after transrectal high‐intensity focused ultrasound (HIFU) therapy for organ‐confined prostate cancer and subsequent treatment failure, as defined by the presence of residual disease at biopsy 6 months after treat...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2006-09, Vol.98 (3), p.537-539
Main Authors: UCHIDA, TOYOAKI, ILLING, ROWLAND O., CATHCART, PAUL J., EMBERTON, MARK
Format: Article
Language:English
Subjects:
ablation
Adenocarcinoma - blood
Adenocarcinoma - therapy
Aged
Aged, 80 and over
Biological and medical sciences
cancer
Genital system. Mammary gland
high‐intensity focused ultrasound
Humans
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
outcome
prostate
Prostate-Specific Antigen - metabolism
Prostatic Neoplasms - blood
Prostatic Neoplasms - therapy
PSA nadir
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Treatment Failure
Tumors of the urinary system
Ultrasound, High-Intensity Focused, Transrectal - methods
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE To explore the association between the prostate‐specific antigen (PSA) nadir after transrectal high‐intensity focused ultrasound (HIFU) therapy for organ‐confined prostate cancer and subsequent treatment failure, as defined by the presence of residual disease at biopsy 6 months after treatment. PATIENTS AND METHODS Between January 1999 and January 2005, 115 patients in a Japanese hospital were treated using a transrectal HIFU system (SonablateTM, Focus Surgery, IN, USA) for presumed localized adenocarcinoma of the prostate. All treatments were primary and none of the patients had received hormone therapy. The PSA level was measured at 2‐monthly intervals and all patients had a transrectal prostate biopsy taken at 6 months. Multiple logistic regression was used to examine the relationship between PSA nadir and treatment failure, as defined by the presence of disease at biopsy. RESULTS The PSA nadir was strongly associated with treatment failure (P 1.0 ng/mL. In addition, the PSA nadir was strongly associated with both preoperative PSA level and residual prostate volume. CONCLUSION There is a clear and intuitive association between the PSA nadir and the risk of treatment failure after HIFU. These data can be used to predict the risk of residual disease in patients with prostate cancer undergoing HIFU therapy. They can also be used to inform where the target PSA nadir should be set for this novel therapy.
ISSN:1464-4096
1464-410X
DOI:10.1111/j.1464-410X.2006.06297.x